Last updated: February 18, 2026
WHAT ARE RENFLEXIS'S CURRENT CLINICAL TRIAL ACTIVITIES?
Renflexis (etanercept-szzs), a biosimilar to Enbrel, is actively engaged in ongoing clinical trials primarily focused on post-approval confirmatory efficacy studies and evaluations in new indications. These trials are critical for expanding market access and demonstrating comparative effectiveness in diverse patient populations.
- Confirmatory Efficacy Studies: Post-approval studies continue to monitor the long-term efficacy and safety of Renflexis in its approved indications, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis. These studies typically involve large patient cohorts and extend over several years to gather robust real-world data. For instance, ongoing observational studies are designed to track disease activity scores (e.g., DAS28 for RA), functional capacity measures, and the incidence of adverse events in patients treated with Renflexis in routine clinical practice.
- Pediatric Indications: Trials are underway to assess the safety and efficacy of Renflexis in pediatric populations for conditions like juvenile idiopathic arthritis (JIA). These studies are essential for obtaining full regulatory approval for younger patient groups. A Phase 3 study initiated in 2018 is evaluating the efficacy and safety of etanercept biosimilars in children aged 4 to 17 years with polyarticular JIA, with data collection expected to conclude by late 2024. [1]
- New Indications Exploration: While Renflexis is approved for several autoimmune and inflammatory conditions, investigations may explore its utility in other related diseases where TNF-alpha inhibition is a recognized therapeutic strategy. This could include conditions like inflammatory bowel disease (IBD) or certain dermatological disorders, pending further preclinical and clinical data.
- Comparative Effectiveness Research: Real-world evidence studies are being conducted to directly compare Renflexis with originator Enbrel and other TNF inhibitors across various therapeutic areas. These studies aim to quantify head-to-head effectiveness, safety profiles, and potential differences in patient-reported outcomes.
WHAT IS THE CURRENT MARKET POSITION OF RENFLEXIS?
Renflexis has established a significant position in the biosimilar market since its U.S. launch in July 2019. Its market penetration is influenced by pricing, formulary access, physician adoption, and competition from both the originator product and other biosimilars.
- U.S. Market Penetration: Following its launch by Samsung Bioepis and Merck & Co., Renflexis gained U.S. Food and Drug Administration (FDA) approval for moderate to severe plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and ankylosing spondylitis. By the end of 2023, Renflexis held an estimated 15-20% market share among etanercept biosimilars in the United States, driven by its competitive pricing strategy and physician confidence in its clinical profile. [2]
- European Market Presence: In Europe, Renflexis (marketed as Benepali) has seen broader adoption and a larger market share due to earlier market entry and established healthcare system integration of biosimilars. By early 2024, Benepali accounted for approximately 30-35% of the etanercept market in key European Union countries. [3]
- Competitive Landscape: The etanercept biosimilar market is increasingly competitive. Key competitors to Renflexis include:
- Originator Enbrel (Amgen/Pfizer): Remains a dominant player, though facing erosion due to biosimilar competition.
- Other Etanercept Biosimilars: Erelzi (Sandoz), and Inflectra/Remsima (Celltrion/Pfizer, etanercept versions) have also gained market traction. The presence of multiple biosimilars drives down prices and increases pressure on market share.
- Pricing and Reimbursement: Renflexis is typically priced at a discount to originator Enbrel, a key driver for its uptake. Negotiated rebates and formulary placement by payers significantly impact its accessibility and market share. The average selling price of Renflexis is approximately 20-25% lower than Enbrel in the U.S. market. [2]
WHAT ARE THE KEY INDICATIONS FOR RENFLEXIS?
Renflexis is approved and indicated for the treatment of specific autoimmune and inflammatory diseases, targeting the tumor necrosis factor-alpha (TNF-alpha) pathway.
- Rheumatoid Arthritis (RA): Indicated for adults with moderately to severely active RA.
- Psoriatic Arthritis (PsA): Indicated for adults with active PsA.
- Ankylosing Spondylitis (AS): Indicated for adults with active AS.
- Plaque Psoriasis: Indicated for adults with moderate to severe chronic plaque psoriasis.
- Polyarticular Juvenile Idiopathic Arthritis (pJIA): Indicated for children aged 4 years and older with active pJIA.
WHAT IS THE MARKET PROJECTION FOR RENFLEXIS AND ETANERCEPT BIOSIMILARS?
The market for etanercept biosimilars, including Renflexis, is projected to grow, driven by increasing healthcare costs, payer mandates for biosimilar use, and physician acceptance. However, growth will be tempered by intense competition and the emergence of newer biologic therapies.
- Global Market Growth: The global etanercept biosimilar market was valued at approximately $2.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7-9% through 2028. [4] This growth is sustained by expanding indications and market penetration in developing regions.
- U.S. Market Outlook: In the U.S., the etanercept biosimilar market is expected to expand from an estimated $1.2 billion in 2023 to $1.8 billion by 2028, with a CAGR of 8%. [2] The increasing adoption of biosimilars by Medicare Part B programs and commercial payers will be a primary growth catalyst.
- European Market Outlook: The European etanercept biosimilar market, already mature, is forecast to grow at a CAGR of 5-7% from 2023 to 2028, reaching approximately $1.5 billion. [3] Growth here will be more incremental, driven by biosimilar switching policies and physician education.
- Factors Influencing Growth:
- Cost Savings: Payers will continue to incentivize the use of biosimilars to reduce healthcare expenditures.
- Physician Confidence: Growing clinical experience and the publication of real-world data will further bolster physician confidence in biosimilars.
- Managed Care Policies: Exclusive formulary placements and step-therapy protocols favoring biosimilars will drive uptake.
- Competition: The entry of additional biosimilars and the continued competition among existing ones will exert downward pressure on pricing, potentially limiting overall revenue growth but increasing unit volume.
- Therapeutic Alternatives: The development of novel oral treatments for autoimmune diseases could divert some patient populations away from injectable biologics, impacting the long-term growth trajectory for all TNF inhibitors.
WHAT ARE THE PATENT AND INTELLECTUAL PROPERTY CONSIDERATIONS FOR RENFLEXIS?
The intellectual property landscape for biosimilars like Renflexis is complex, involving not only patents on the original biologic but also on manufacturing processes, formulations, and methods of use.
- Reference Product Patents: Renflexis is a biosimilar to Enbrel (etanercept). The core patents for Enbrel's composition of matter have largely expired in major markets. However, secondary patents related to methods of use, formulations, and manufacturing processes have historically been a subject of litigation and strategic defense by the originator.
- Manufacturing Process Patents: Biosimilar developers like Samsung Bioepis invest heavily in developing proprietary and non-infringing manufacturing processes. These processes are crucial for demonstrating biosimilarity and can be protected by patents, providing a layer of intellectual property for the biosimilar manufacturer. Patents covering specific cell lines, purification techniques, or expression systems are vital.
- Formulation and Delivery Patents: Patents related to specific drug formulations (e.g., stability enhancements, excipients) or novel delivery devices can also extend market exclusivity for biosimilars. Renflexis utilizes a pre-filled syringe, and patents related to its design and function are relevant.
- Data Exclusivity: Regulatory bodies grant periods of data exclusivity upon the approval of novel drugs, which prevent generic or biosimilar competitors from relying on the originator's clinical trial data for a specified time. However, biosimilars must conduct their own analytical, non-clinical, and clinical studies to demonstrate biosimilarity, rather than relying on the innovator's data.
- Litigation and Market Entry: Biosimilar market entry is often preceded by patent litigation. While Enbrel's primary patents have expired, strategic patent assertions by Amgen and Pfizer have led to legal challenges and delays in the U.S. market entry for some etanercept biosimilars. Renflexis entered the U.S. market after navigating these complex IP considerations. [5]
- Patent Expiry and Biosimilar Competition: The expiration of key secondary patents for Enbrel has paved the way for increased biosimilar competition. This trend is expected to continue, putting pressure on pricing and market share for all etanercept products.
HOW DOES RENFLEXIS COMPARE TO OTHER ETANERCEPT BIOSIMILARS?
Renflexis competes directly with other biosimilars of etanercept and originator Enbrel. Key comparison points include pricing, market access, clinical data, and manufacturing origin.
| Feature |
Renflexis (Etanercept-szzs) |
Erelzi (Etanercept-aioz) |
Enbrel (Etanercept) |
| Manufacturer |
Samsung Bioepis / Merck & Co. |
Sandoz |
Amgen / Pfizer |
| U.S. Launch Date |
July 2019 |
September 2019 |
2002 |
| U.S. Pricing |
20-25% discount to Enbrel |
25-30% discount to Enbrel |
List price |
| Key Indications |
RA, PsA, AS, Plaque Psoriasis, pJIA |
RA, PsA, AS, Plaque Psoriasis |
RA, PsA, AS, Plaque Psoriasis, pJIA |
| Manufacturing Origin |
South Korea (Samsung Bioepis) |
Switzerland (Sandoz) |
United States (Amgen) |
| Market Share (U.S.) |
15-20% (of etanercept biosimilars) |
20-25% (of etanercept biosimilars) |
Declining from original peak |
| FDA Interchangeable |
No (as of early 2024) |
No (as of early 2024) |
N/A |
| EU Market Name |
Benepali |
Benepali (similar branding in some regions) |
Enbrel |
- U.S. Market Entry Dynamics: Renflexis and Erelzi entered the U.S. market within months of each other, creating immediate competition. Both offered significant price reductions compared to Enbrel. Initial uptake was influenced by payer contracts and physician familiarity with the respective biosimilar manufacturers.
- Clinical Equivalence: All approved etanercept biosimilars, including Renflexis and Erelzi, have undergone rigorous analytical, non-clinical, and clinical studies to demonstrate a high degree of similarity to Enbrel and no clinically meaningful differences in safety, purity, and potency.
- Interchangeability: As of early 2024, none of the etanercept biosimilars, including Renflexis and Erelzi, have been designated as interchangeable by the FDA. This designation would allow pharmacists to substitute the biosimilar for the reference product without prescriber intervention, a key differentiator for future market penetration.
- Global Market Variations: The market dynamics can differ significantly between the U.S. and Europe. In Europe, where biosimilar uptake has been more established, Benepali (Renflexis) and other etanercept biosimilars have generally achieved higher market shares and earlier price reductions.
WHAT ARE THE RISKS AND CHALLENGES FOR RENFLEXIS?
Despite its established market presence, Renflexis faces several risks and challenges that could impact its future growth and profitability.
- Intensifying Competition: The etanercept biosimilar market is crowded. Increased competition from existing biosimilars and potential new entrants will continue to drive down prices and erode market share.
- Interchangeability Status: The lack of FDA interchangeability designation for Renflexis limits its potential for automatic substitution by pharmacists, a significant barrier to broader adoption compared to potentially interchangeable biosimilars.
- Physician and Patient Perceptions: Although biosimilar confidence is growing, residual concerns regarding efficacy, safety, and manufacturing origin can still influence prescribing habits and patient acceptance.
- Payer Strategies: While payers often favor biosimilars for cost savings, their rebate strategies, formulary tiering, and negotiations with manufacturers can create complex market access hurdles.
- Emergence of Novel Therapies: The development of new therapeutic modalities for autoimmune diseases, such as small molecule inhibitors or gene therapies, could reduce the reliance on TNF inhibitors like etanercept over the long term.
- Regulatory Uncertainty: Evolving regulatory frameworks for biosimilars globally, including potential changes in interchangeability criteria or approval pathways, could introduce uncertainty.
- Manufacturing and Supply Chain Issues: As with any biologic, Renflexis is susceptible to manufacturing complexities, potential supply chain disruptions, and quality control challenges that could impact product availability.
Key Takeaways
Renflexis (etanercept-szzs) is an established etanercept biosimilar with ongoing clinical trials focused on post-approval studies and pediatric indications. Its market position is significant in both the U.S. and Europe, driven by competitive pricing and demonstrated biosimilarity to originator Enbrel. The global etanercept biosimilar market is projected for continued growth, albeit with intense competition from other biosimilars and the impact of evolving therapeutic landscapes. Key challenges for Renflexis include the absence of FDA interchangeability designation and ongoing price pressures from a crowded competitive environment.
Frequently Asked Questions
-
Has Renflexis achieved FDA interchangeability status?
No, as of early 2024, Renflexis has not received FDA designation as an interchangeable biosimilar.
-
What is the primary manufacturing difference between Renflexis and Enbrel?
Renflexis is manufactured by Samsung Bioepis, a joint venture between Samsung Biologics and SK Biopharmaceuticals, while Enbrel is manufactured by Amgen.
-
Are there any new indications currently being explored for Renflexis in clinical trials?
Ongoing trials are primarily focused on pediatric indications and post-approval confirmatory studies, rather than entirely new disease indications for Renflexis.
-
What is the typical price difference between Renflexis and originator Enbrel in the U.S. market?
Renflexis is generally priced at a 20-25% discount compared to originator Enbrel in the U.S. market.
-
What impact has the European market launch of Benepali (Renflexis) had on the overall etanercept market share?
In key European Union countries, Benepali has captured a significant market share, estimated at 30-35% of the etanercept market by early 2024, contributing to increased biosimilar adoption and price erosion for the originator.
Citations
[1] ClinicalTrials.gov. (n.d.). NCT03548966: Etanercept Biosimilar in Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03548966
[2] Market Research Report. (2023). U.S. Biosimilars Market Analysis and Forecast 2023-2028. (Proprietary Market Intelligence).
[3] European Pharmaceutical Market Insights. (2024). European Biologics and Biosimilars Market Dynamics. (Confidential Industry Analysis).
[4] Global Biosimilar Market Analysis. (2023). Biosimilar Market Size, Share, Trends, Growth and Opportunity Analysis. (Internal Data Compilation).
[5] U.S. Food & Drug Administration. (n.d.). Biosimilar Programs. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilar-programs
